1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Presented at the American Cancer Society Workshop on Guidelines for Breast Cancer Detection, Chicago, Illinois, March 8, 1997.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Screening mammography beginning at age 40 years†
A reappraisal of cost-effectiveness
Article first published online: 31 OCT 2000
DOI: 10.1002/(SICI)1097-0142(19980601)82:11<2235::AID-CNCR19>3.0.CO;2-V
Copyright © 1998 American Cancer Society
Additional Information
How to Cite
Rosenquist, C. J. and Lindfors, K. K. (1998), Screening mammography beginning at age 40 years. Cancer, 82: 2235–2240. doi: 10.1002/(SICI)1097-0142(19980601)82:11<2235::AID-CNCR19>3.0.CO;2-V
- †
Publication History
- Issue published online: 31 OCT 2000
- Article first published online: 31 OCT 2000
- Manuscript Revised: 12 DEC 1997
- Manuscript Received: 19 AUG 1997
- Manuscript Accepted: 16 JAN 1997
- Abstract
- Article
- References
- Cited By
Keywords:
- mammography;
- screening;
- cost-effectiveness;
- breast;
- carcinoma
Using a Markov model, data from recent studies on the benefit of screening mammography were used to reassess the cost-effectiveness of this procedure. The marginal cost per year-life saved was within the acceptable range for all the screening strategies evaluated. These data may be useful in health policy decision-making.
Abstract
BACKGROUND
Several recent studies have added significant information regarding the benefit of screening mammography, especially in the 40-49-years age group. This new information makes it important to reassess the cost-effectiveness of screening.
METHODS
A Markov model was used to study the cost-effectiveness of 4 age-related screening strategies: 1) annually from ages 40-79 years; 2) annually from ages 40-64 years and biennially from ages 65-79 years; 3) annually from ages 40-49 years and biennially from ages 50-79 years; and 4) annually from ages 40-79 years in high risk women (10%) and biennially from ages 40-49 years followed by annually from ages 50-79 years in normal risk women (90%). An additional strategy simulating hormone status and estrogen exposure was evaluated. Cost-effectiveness was expressed as marginal cost per year-life saved (MCYLS).
RESULTS
The MCYLS varied from $18,800 to $16,100. For all strategies this was within the range of other generally acceptable diagnostic and therapeutic medical procedures. There was a 14% decrease in MCYLS from the least cost-effective to the most cost-effective strategy.
CONCLUSIONS
Cost-effectiveness of four age-related mammographic screening strategies was evaluated. The MCYLS for all strategies was within a generally accepted range. With increasing concerns regarding the cost of health care, this information may be useful in health policy decision-making. Cancer 1998;82:2235-2240. © 1998 American Cancer Society.